Jun 15, 2017 11:15 JST

Source: Alset International Ltd

First-Year Performance of Global Systematic Multi-Strategy Fund

SINGAPORE, Jun 15, 2017 - (ACN Newswire) - The Board of Directors of Singapore eDevelopment Ltd ("SeD" or "the Group") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation. The net returns are calculated by its fund administrator, Maples Fund Services.

Launched on 1 June 2016, the GSMS Fund adopts an "all-weather" strategy that seeks to produce consistent risk-adjusted returns regardless of market volatility. The GSMS Fund employs a systematic approach focusing on liquid exchange traded securities that are diversified across asset classes, geographical regions and time-frames.

HFAM intends to allow investors the option to receive 100% of the net profits (after all fees) on an annual basis or to reinvest all profits back into the fund. HFAM also intends to offer the GSMS Fund to global fund of funds.

HFAM is a registered fund management company regulated by the Monetary Authority of Singapore. As at the date of this announcement, HFAM manages two (2) live funds, namely, the GSMS Fund and Global Opportunity Fund. As announced by the Company on 15 May 2017, HFAM also intends to manage two (2) additional funds, namely, Global Property Development Fund and Global High Yield Income Fund. The Company will make subsequent announcements to update its shareholders when there are material updates as may be necessary or appropriate.

The acquisition of HFAM is part of the Group's efforts to develop new revenue streams and is in line with the Group's pursuit of providing capital services and creating opportunities to accelerate SeD's corporate recovery.

SeD website: www.sed.com.sg
HFAM website: www.hf-asset.com

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

Issued on behalf of the Company:
WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01, Royal Group Building
Singapore 048693
Mr Ian Lau
E: ianlau@wer1.net
T: +65 6737 4844

Source: Alset International Ltd
Sectors: Funds & Equities

Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Related Press Release


Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities
March 23 2022 09:00 JST
 
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
February 21 2022 12:00 JST
 
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
 
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
 
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
 
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
 
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
 
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
 
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
 
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>